Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Provided By Globe Newswire – Last update:

 - Oral fadraciclib demonstrated good tolerability with continuous dosing; 
anticipate entering Phase 2 POC stage in 2H 2022 –

Read more at globenewswire.com